NIELSENIQ
9.2.2021 10:02:07 CET | Business Wire | Press release
The NielsenIQ Connect Partner Network (CPN) has expanded its business globally into Asia and Europe, broadening the reach and influence of the network while also providing partners access to global data sets.
As the Consumer Packaged Goods (CPG) industry’s largest open ecosystem of tech-driven solution providers, the NielsenIQ Connect Partner Network has continued on its growth trajectory by selectively adding innovative partners since its launch in 2016. Now, by entering new markets, the network will expand its value to both clients and partners across the globe.
“The NielsenIQ Connect Partner Network is not only core to the success and growth of Nielsen, but also to the CPG industry as a whole”, said Johan Sjostrand, Global President Retail Intelligence, NielsenIQ. “In addition to the network expanding into global markets, it is also continuously growing by way of the number of member companies, as we recently surpassed 100 partners. We are able to continuously attract powerful partners because we never stop evolving our ways of working with them, and the opportunities and benefits provided to them. The network is a win for our clients, our partners, and NielsenIQ overall, which makes the network so unique and leads us to believe its influence will only expand from here.”
Partners are provided with streamlined access to industry-leading data, enabling them to enhance their own solutions. The diversity of markets that Asia and Europe encompass will provide unique opportunities and benefits to the CPG industry as a whole.
In a recent survey conducted by the NielsenIQ Connect Partner Network team, 83% of partners responded that the network has helped them create a stronger, better offering for their clients, while over 90% of partners said they were able to identify new opportunities due to their membership. NielsenIQ clients also benefit a great deal, as they can work directly with any of our partners who specialize across a broad range of areas including demand planning, data harmonization, machine learning, and AI-driven promotion, to name a few. With the NielsenIQ Connect Partner Network, clients and partners work with a common dataset, enabling them to easily bridge insights and save time typically spent figuring out who to work with, how to get data to who they decide to work with, and how to make sense of disparate data sources.
“We are extremely excited about the global expansion of NielsenIQ’s Connect Partner Network and what this means for us and our clients'', said Satish Raman, Chief Strategy Officer, Fractal Analytics. “One of the things we love most about the network is its openness, enabling us to freely and easily collaborate with NielsenIQ, our clients and other Connected Partners in the network. The opportunity to scale that collaboration globally will open more avenues to enter new markets, expand our client base, increase the depth and breadth of our engagements, and drive our solution and product enhancements. This is a profound step forward for the network and big news for NielsenIQ, but I also see this as big news for Fractal and all other partners, because any enhancement to the network will ultimately add value to us and our clients.”
“We are very proud of the success, expansion, and continued growth of the Network”, said Brett Jones, SVP, Global Leader, NielsenIQ Connect Partner Network. “Making this network truly global is a major milestone for us. It has always been our goal to evolve in a variety of ways, whether that be through the addition of new partners, the enhancement of our offerings, or entering new markets like we are now with Asia and Europe. There are even bigger things ahead for the Connected Partner Network as we never stop exploring avenues to positively impact the CPG landscape.”
For additional information, or if you are interested in becoming a NielsenIQ Connect Partner Network member, please go to https://www.nielsen.com/us/en/solutions/capabilities/connected-partner-program/ . For a list of all partners please go to https://microsites.nielsen.com/connectedpartnernetwork/
ABOUT NIELSEN
Nielsen Holdings plc (NYSE: NLSN) is a global measurement and data analytics company that provides the most complete and trusted view available of consumers and markets worldwide. Nielsen is divided into two business units. Nielsen Global Media provides media and advertising industries with unbiased and reliable metrics that create a shared understanding of the industry required for markets to function. NielsenIQ (formerly known as Nielsen Global Connect) provides consumer packaged goods manufacturers and retailers with accurate, actionable information and insights and a complete picture of the complex and changing marketplace that companies need to innovate and grow.
Our approach marries proprietary Nielsen data with other data sources to help clients around the world understand what’s happening now, what’s happening next, and how to best act on this knowledge.
An S&P 500 company, Nielsen has operations in nearly 100 countries, covering more than 90% of the world’s population. For more information, visit www.nielsen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom